DRRX Durect Corp. featured news, full reports, and detailed charts
Durect Corp. (DRRX) Wrap Up:
Durect Corporation, a specialty pharmaceutical company, engages in developing pharmaceutical products based on proprietary drug delivery technology platforms. Its products under Phase II clinical trials include POSIDUR, a release injectable to deliver bupivacaine, an off-patent anesthetic agent; TRANSDUR-Sufentanil, a transdermal sufentanil patch that uses TRANSDUR delivery system to deliver sufentanil, an opioid medication; and ELADUR, a transdermal bupivacaine patch, which uses TRANSDUR transdermal technology and provides continuous delivery of bupivacaine for up to three days from a single application. The company’s product portfolio also comprises CHRONOGESIC pain therapy system, an osmo...Durect Corp. (DRRX:NASDAQ)
Snapshot of Durect Corp. (DRRX)
|
OPEN
$2.12
|
PREVIOUS CLOSE
$2.11
|
|
|
DAY HIGH
$2.20
|
DAY LOW
$2.06
|
|
|
52 WEEK HIGH
11/28/08 - $4.26
|
52 WEEK LOW
03/5/09 - $1.40
|
|
|
MARKET CAP
181.3M
|
AVERAGE VOLUME 3 mo
158.3K
|
|
|
DILUTED EPS TTM
$-0.49
|
SHARES OUTSTANDING
86.7M
|
|
|
DRRX Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
DRRX Top Compensated Officers
Executives, Board Directors
Key developments for Durect Corp. (DRRX)
Durect Corp. expected to Report Fiscal Year 2009 Results on February 12, 2010. This event was calculated by Capital IQ (Created on November 2, 2009).
Durect Corp. reported earnings unaudited results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported total revenues were $8.4 million compared to $6.6 million for the same period in 2008; revenues in the 2009 period included $3.0 million related to the sale of certain excipients used in REMOXY® to King Pharmaceuticals in 2008 and the first quarter of 2009, all of which was recognized upon the execution of the long term supply agreement between us and King in the third quarter of 2009. Net loss was $5.5 million or $0.07 per basic and diluted share compared to a net loss of $9.2 million or $0.11 per basic and diluted share for the same period in 2008. Loss from operations was $8.38 million compared to $6.63 million in third quarter of 2008. For the nine months ended September 30, 2009, the company reported net loss of $21.7 million or $0.26 per basic and diluted share on total revenues of $19.41 million compared to a net loss of $25.56 million or $0.33 per basic and diluted share on total revenues of $19.38 million for the same period in 2008. Loss from operations was $19.41 million compared to $19.38 million in nine months of 2008.
Durect Corp., Q3 2009 Earnings Call, Oct 29 2009
DRRX Competitors
| Company | Last | Change |
| Alexza Pharmaceuticals Inc | $2.28 USD | +0.06 |
| Depomed Inc | $3.30 USD | +0.03 |
| Flamel Technologies SA | $7.48 USD | +0.12 |
| Inovio Biomedical Corp | $1.53 USD | +0.33 |
| Javelin Pharmaceuticals Inc | $1.47 USD | +0.07 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | DRRX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 6.4x |
|
| Price/Book | 5.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 5.0x |
|
|
DRRX |
||
DRRX transactions
| Type Date |
Target |
|
Private Placement
September 10, 2009 |
-- |